Skip to content

Study · Observational study · n = 3,173 · 2015

5 results

The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication.

von Scholten BJ, Ørsted DD, Svendsen AL, Persson F, Rossing P

Journal of diabetes and its complications13 Aug 2015Cited by 9 (Europe PMC)

PMID26345339 (opens in a new tab)DOI10.1016/j.jdiacomp.2015.08.007 (opens in a new tab)PepBankPUB-26345339
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes, body weight changed by -1.9 kg with liraglutide, compared with 0.2 kg with comparator drugs.

    In plain wordsIn patients with type 2 diabetes, body weight fell by about 1.9 kg with liraglutide, compared with a small change with other drugs.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change
    Study

    n = 3,173

    Comparator
    Insulin glargine, glimepiride, exenatide and rosiglitazone (pooled comparator)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    body weight change
    −1.9 kg
    liraglutide
    body weight change
    0.2 kg
    comparator

    Source sentences

    Summary
    For liraglutide, BW changed -1.9 (95% CI (-2.0; -1.8)) kg, for comparator BW changed 0.2 (95% CI (0.03; 0.3)) kg.
    2 context sentences
    Summary · context
    Data were pooled from the six LEAD (Liraglutide Effect and Action in Diabetes) trials and the LIRA-DPP4 trial.
    Summary · context
    We investigated changes in eGFR for patients treated with liraglutide, and for patients treated with glucose-lowering medications with less weight-reducing effects (insulin glargine, glimepiride, exenatide and rosiglitazone).
  2. 02HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes treated with liraglutide, a 10% body weight decrease yielded no change in creatinine.

    In plain wordsIn patients with type 2 diabetes on liraglutide, losing weight was not linked to a change in creatinine, a kidney marker.

    Peptide
    Liraglutide
    Outcome
    No significant changeCreatinine with 10% body weight decrease
    Study

    n = 3,173

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Using regression modelling, a 10% BW decrease yielded no change in creatinine, MDRD eGFR or CKD-EPI eGFR for both liraglutide and comparator
    2 context sentences
    Summary · context
    Data were pooled from the six LEAD (Liraglutide Effect and Action in Diabetes) trials and the LIRA-DPP4 trial.
    Summary · context
    We investigated changes in eGFR for patients treated with liraglutide, and for patients treated with glucose-lowering medications with less weight-reducing effects (insulin glargine, glimepiride, exenatide and rosiglitazone).
  3. 03HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes treated with liraglutide, a 10% body weight decrease yielded no change in MDRD eGFR.

    In plain wordsIn patients with type 2 diabetes on liraglutide, losing weight was not linked to a change in one estimate of kidney function.

    Peptide
    Liraglutide
    Outcome
    No significant changeMDRD eGFR with 10% body weight decrease
    Study

    n = 3,173

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Using regression modelling, a 10% BW decrease yielded no change in creatinine, MDRD eGFR or CKD-EPI eGFR for both liraglutide and comparator
    2 context sentences
    Summary · context
    Data were pooled from the six LEAD (Liraglutide Effect and Action in Diabetes) trials and the LIRA-DPP4 trial.
    Summary · context
    We investigated changes in eGFR for patients treated with liraglutide, and for patients treated with glucose-lowering medications with less weight-reducing effects (insulin glargine, glimepiride, exenatide and rosiglitazone).
  4. 04HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes treated with liraglutide, a 10% body weight decrease yielded no change in CKD-EPI eGFR.

    In plain wordsIn patients with type 2 diabetes on liraglutide, losing weight was not linked to a change in another estimate of kidney function.

    Peptide
    Liraglutide
    Outcome
    No significant changeCKD-EPI eGFR with 10% body weight decrease
    Study

    n = 3,173

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Using regression modelling, a 10% BW decrease yielded no change in creatinine, MDRD eGFR or CKD-EPI eGFR for both liraglutide and comparator
    2 context sentences
    Summary · context
    Data were pooled from the six LEAD (Liraglutide Effect and Action in Diabetes) trials and the LIRA-DPP4 trial.
    Summary · context
    We investigated changes in eGFR for patients treated with liraglutide, and for patients treated with glucose-lowering medications with less weight-reducing effects (insulin glargine, glimepiride, exenatide and rosiglitazone).
  5. 05HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes treated with liraglutide, a 10% body weight decrease was associated with a 10.2% decrease in Cockcroft-Gault eGFR, which includes body weight.

    In plain wordsIn patients with type 2 diabetes on liraglutide, weight loss was linked to a lower weight-based kidney estimate, but not to a change in creatinine.

    Peptide
    Liraglutide
    Outcome
    DecreaseCockcroft-Gault eGFR with 10% body weight decrease
    Study

    n = 3,173

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    Cockcroft-Gault eGFR decrease
    10.2%
    liraglutide, per 10% body weight decrease

    Source sentences

    Summary
    but was associated with a 10.2% (-11.3%; -9.1%) decrease in CG eGFR for liraglutide, and a 10.6% (-12.0%; -9.1%) decrease for comparator.
    2 context sentences
    Summary · context
    Data were pooled from the six LEAD (Liraglutide Effect and Action in Diabetes) trials and the LIRA-DPP4 trial.
    Summary · context
    We investigated changes in eGFR for patients treated with liraglutide, and for patients treated with glucose-lowering medications with less weight-reducing effects (insulin glargine, glimepiride, exenatide and rosiglitazone).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.